Compare AbbVie Inc (ABBV) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

AbbVie IncTrade

iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $249.28 (market cap $441.94B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.34. The key difference: AbbVie Inc pays a 2.77% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

	ABBV	TLT
Market Cap	$441.94B	—
Sector	Health	—
52-Week High	$263.58	$92.06
52-Week Low	$197.38	$82.05
Enterprise Value	$506.19B	—
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

iShares 20 Plus Year Treasury Bond ETF

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.40, up 0.43% on the day, amid a bearish technical signal with selling pressure dominating moving averages. Recent news highlights rising Treasury yields and inflation concerns, with institutional buying noted. The ETF provides exposure to long-term U.S. government bonds, with dividend distributions continuing regularly.

Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income but facing headwinds from potential Fed policy shifts. Key risks include yield volatility and macroeconomic factors impacting bond prices.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

TLT

Theralase announces up to C$5M private placement to fund cancer and virus treatment studiesNewsfile Corp · 1 day agoBullish Theralase grants 7M stock options at C$0.265, vesting over 3 years, to support its cancer and virus treatment R&D.Newsfile Corp · 4 days agoNeutral View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.